Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-13
2007-11-13
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S321000, C514S323000, C514S326000, C514S327000, C514S330000, C514S331000, C546S197000, C546S201000, C546S207000, C546S216000, C546S225000, C546S229000, C546S236000, C546S237000, C546S238000, C546S240000
Reexamination Certificate
active
10771519
ABSTRACT:
One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.
REFERENCES:
patent: 3806595 (1974-04-01), Jaggers et al.
patent: 3876769 (1975-04-01), Mallion et al.
patent: 3959273 (1976-05-01), Mallion et al.
patent: 4033951 (1977-07-01), Maiser
patent: 4241059 (1980-12-01), Hauck et al.
patent: 4593036 (1986-06-01), Lassen et al.
patent: 4605654 (1986-08-01), Cousse et al.
patent: 5328917 (1994-07-01), Jakobsen et al.
patent: 5521180 (1996-05-01), Fujii et al.
patent: 6110937 (2000-08-01), Loughhead et al.
patent: 6124317 (2000-09-01), Bigge et al.
patent: 6124323 (2000-09-01), Bigge et al.
patent: 6645980 (2003-11-01), Cuny et al.
patent: 6653478 (2003-11-01), Urbanski et al.
patent: 6703383 (2004-03-01), Wu et al.
patent: 6703508 (2004-03-01), Aquila et al.
patent: 2003/0050309 (2003-03-01), Aquila et al.
patent: 2004/0209846 (2004-10-01), Cuny et al.
patent: 0 000 693 (1979-02-01), None
patent: 0 076 089 (1983-04-01), None
patent: 0 080 940 (1983-06-01), None
patent: 0 138 716 (1985-04-01), None
patent: 0 229 623 (1987-07-01), None
patent: 0266 574 (1988-05-01), None
patent: 0 290 958 (1988-11-01), None
patent: 0 639 568 (1995-02-01), None
patent: 1221294 (1960-06-01), None
patent: 2 248 049 (1975-05-01), None
patent: 2 471 378 (1981-06-01), None
patent: 2 534 915 (1984-04-01), None
patent: 2 553 441 (1985-04-01), None
patent: 2 564 462 (1985-11-01), None
patent: 1138405 (1969-01-01), None
patent: 1184023 (1970-03-01), None
patent: 1 260 886 (1972-01-01), None
patent: 1 382 526 (1975-02-01), None
patent: 1 382 965 (1975-02-01), None
patent: 1 452 701 (1976-10-01), None
patent: 1 501 321 (1978-02-01), None
patent: 111542 (1965-06-01), None
patent: WO91/09032 (1991-06-01), None
patent: WO92/01672 (1992-02-01), None
patent: WO92/02502 (1992-02-01), None
patent: WO93/15052 (1993-08-01), None
patent: WO94/13291 (1994-06-01), None
patent: WO95/03302 (1995-02-01), None
patent: WO95/25732 (1995-09-01), None
patent: WO95/33722 (1995-12-01), None
patent: WO95/33723 (1995-12-01), None
patent: WO98/51668 (1998-11-01), None
patent: WO/99/65487 (1999-12-01), None
patent: WO 00/09491 (2000-02-01), None
patent: WO 0071518 (2000-11-01), None
patent: WO 01/32178 (2001-05-01), None
patent: WO 01/68604 (2001-09-01), None
patent: WO 01/92226 (2001-12-01), None
patent: WO 2005/077463 (2005-08-01), None
Engelstoft and Hansen; “Synthesis and 5HT Modulating Activity of Stereoisomers of 3-Phenoxymethyl-4-Phenylpiperidines” Acta Chemica Scandinavica 50:164-169, (1996).
O'Neill et al., “Effect of Ca2+and Na+Channel Inhibitors in Vitro and In Global Cerebral Ischaemia in Vivo”, European Journal of Pharmacology 332: 121-131, (1997).
Balsamo et al., “-[2-Ethoxyphenoxy)methyl]piperidine Derivatives. Synthesis and Antidepressant Activity,” J. Med. Chem., 30: 222-225 (1987).
International Search Report Completed on Feb. 27, 2002 and Mailed on Mar. 13, 2002.
Volkow, et al., “Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate”, Am. J. Psychiatry, 155:10, pp. 1325-1331 (1998).
Balster, et al., “Fixed-Interval Schedule of Cocaine Reinforcement: Effect Of Dose and Infusion Duration1”, Journal of the Exper. Analysis of Behavior, 1973, 20, pp. 119-129.
Ritz, et al., “Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine”, Science, vol. 237, pp. 1219-1223, 1987.
Volkow, et al., “Methylphenidate and Cocaine Have A Similar In Vivo Potency To Block Dopamine Transporters In The Human Brain”, Life Sciences, vol. 65, No. 1, pp. PL 7-12, (1999).
Parran, Jr., et al., “Intravenous Methylphenidate Abuse Prototype for Prescription Drug Abuse”, Arch, Intern. Med., vol. 151, pp. 781-783 (1991).
Volkow, et al., “Is Methylphenidate Like Cocaine?”, Arch. Gen. Psychiatry, vol. 52, pp. 456-463, (1995).
Klein, et al., “Clinical Efficacy of Methylphenidate in Conduct Disorder With and Without Attention Deficit Hyperactivity Disorder”, Arch. Gen. Psychiatry, vol. 54, pp. 1073-1080 (1997).
Schweri, et al., “[3H]Threo-(±)-Methylphenidate Binding to 3,4-Dihydroxyphenylethylamine Uptake Sites in Corpus Striatum: Correlation with the Stimulant Properties of Ritalinic Acid Estes”, Journal of Neurochemistry, vol. 45,No. 4, pp. 1062-1070 (1985).
Ding, et al., “Pharmacokinetics and In Vivo Specificity of [11C]dl-threo-Methylphenidate for the Presynaptic Dopaminergic Neuron”, Synapse 18:152-160 (1994).
Madras, et al., “Effects of Cocaine and Related Drugs in Nonhuman Primates. I. [3H]Cocaine Binding Sites in Caudate-Putamen1”, The Journal of Pharmacology and Experimental Therapeutics, vol. 251, No. 1, pp. 131-141, 1989.
Andersson et al., 2001, CAS: 135::242140.
Brown et al., 1990, CAS: 112:35578.
Kutsuki et al., 1990, CAS: 112:7363.
Nagahara et al., 1994, CAS: 120:323168.
International Search Report dated Jun. 29, 2005.
Jones et al., “The Medical Benefit 5-HT Research,” Pharmacology, Biochemistry and Behavior 71:555-568 (2002).
Aquila Brian M.
Bannister Thomas D.
Cuny Gregory D.
Hauske James R.
Holland Joanne M.
Coleman Brenda
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Sepracor Inc.
LandOfFree
Method of treating addiction or dependence using a ligand... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating addiction or dependence using a ligand..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating addiction or dependence using a ligand... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862320